ClinicalTrials.gov
Cure8 trial brief
Why This Matters
A new Phase 2 trial is testing afimkibart (RO7790121) for moderate-to-severe Crohn's disease; people with Crohn's disease who have failed prior treatments may be especially interested in emerging therapies.
Who Should Pay Attention
Adults with moderate-to-severe Crohn's disease (especially those with inadequate response or intolerance to prior therapies), IBD clinicians, and researchers tracking new therapeutic candidates.
Study Snapshot
Story typeClinical Reference
Trial phasePhase 2
Enrollment21 participants
Study statusActive_not_recruiting
Source depthTrial registry record
What To Know
This is a Phase 2, double-blind, randomized induction and maintenance trial with an open-label extension that will evaluate safety and efficacy of afimkibart in adults (18–75) with moderate-to-severe Crohn's disease.
The record lists planned enrollment of 21 participants and primary safety outcomes focused on treatment-emergent adverse events, serious adverse events, and discontinuations. Participants must have prior inadequate response or intolerance to at least one conventional or advanced therapy. The study is active but not recruiting and includes multiple U.S.
sites.
Keep In Mind
This ClinicalTrials.gov record is a trial registration (Phase 2, active_not_recruiting) that lists study design and safety-focused primary outcomes but does not report results. Planned enrollment is small (21), so any findings would be preliminary; consult published peer-reviewed reports when available.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorHoffmann-La Roche
Trial IDNCT05910528
Study typeInterventional
Trial phasePhase 2
Enrollment21 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedSep 16, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)
This Phase 2a trial tested a new investigational drug, tulisokibart, in people with moderately to severely active Crohn’s disease who have not done well on prior therapies — so patients and clinicians watching new...
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
This trial tests an oral integrin α4β7 inhibitor for Crohn’s disease, a new small-molecule approach aiming to block gut-specific immune cell trafficking similar to existing biologic anti‑integrin drugs. If effective and...
DB-3Q for the Treatment of Medically Refractory Crohn's Disease
This trial tests a novel cell-derived extracellular vesicle therapy (DB-3Q) for people with Crohn’s disease who have not responded to standard advanced therapies. It may offer a different biologic approach if proven safe...